News|Articles|November 4, 2026

Urban Hospital Care Narrows, but Doesn't Close, Rural HF Mortality Gap

Fact checked by: Ashley Gallagher, MA
Listen
0:00 / 0:00

Key Takeaways

  • Disentangling residence from hospital effects in 735,460 Medicare beneficiaries showed hospital rurality strongly influenced consultation, diagnostic intensity, GDMT uptake, and outcomes after HFrEF hospitalization.
  • Rural patients in urban hospitals had markedly higher cardiology consultation (OR, 2.02) and greater 90-day GDMT use, including SGLT2 inhibitors (OR, 1.48), versus rural patients in rural hospitals.
SHOW MORE

Rural residents with HFrEF got more specialty care and therapy at urban hospitals but still had higher early mortality than urban patients there.

Rural patients hospitalized for heart failure with reduced ejection fraction (HFrEF) received more cardiology consultation and guideline-directed medical therapy (GDMT) and had lower mortality when treated at urban rather than rural hospitals, yet they still faced higher short-term mortality than urban patients treated in urban hospitals, according to a study published in JAMA Cardiology.1

Rural-urban disparities in HF care and outcomes are well documented, but it has been unclear whether they stem mainly from where patients live, the resources of the hospitals treating them, or both. An earlier analysis of 774,419 patients in the Get With The Guidelines–Heart Failure registry found that patients at rural hospitals were less likely to be prescribed several guideline-recommended therapies, although in-hospital mortality and 30-day postdischarge outcomes were similar to those at urban hospitals.2

To separate patient and hospital effects, the investigators analyzed Medicare fee-for-service beneficiaries discharged alive after an index HFrEF hospitalization from 2013 to 2021.1 Patient residence and hospital location were classified using Rural-Urban Commuting Area codes. Of 735,460 patients (median age, 77 years), 69,061 (9.4%) were rural patients in rural hospitals, 65,510 (8.9%) were rural patients in urban hospitals, 582,947 (79.3%) were urban patients in urban hospitals, and 17,942 (2.4%) were urban patients in rural hospitals. The primary outcome was 90-day all-cause mortality.

Urban Hospitals Doubled Odds of Cardiology Consultation for Rural Patients

Among rural patients, those hospitalized in urban hospitals had twice the odds of receiving an inpatient cardiology consultation (OR, 2.02; 95% CI, 1.84-2.22) and were more likely to undergo inpatient echocardiography (OR, 1.10; 95% CI, 1.04-1.17).

At 90 days after discharge, rural patients treated in urban hospitals had higher use of β-blockers (OR, 1.20; 95% CI, 1.16-1.25), angiotensin receptor-neprilysin inhibitors (ARNIs; OR, 1.23; 95% CI, 1.13-1.34), mineralocorticoid receptor antagonists (MRAs; OR, 1.23; 95% CI, 1.15-1.31), and sodium-glucose cotransporter 2 inhibitors (OR, 1.48; 95% CI, 1.32-1.67). They were, however, less likely to complete outpatient follow-up within 14 days (OR, 0.90; 95% CI, 0.84-0.96).

Rural patients treated in urban hospitals also had lower rates of all-cause and HF readmission and lower odds of death at every time point measured. In Cox models, they had a lower 1-year hazard of HF hospitalization (HR, 0.86; 95% CI, 0.84-0.89; P < .001) and mortality (HR, 0.93; 95% CI, 0.91-0.95; P < .001) than those treated in rural hospitals.

Rural Residence Linked to Higher 30-Day Mortality, Even in Urban Hospitals

Compared with urban patients in urban hospitals, rural patients in the same setting were more likely to receive cardiology consultation (OR, 1.38; 95% CI, 1.31-1.44) and 14-day follow-up (OR, 1.15; 95% CI, 1.11-1.20). Differences in postdischarge GDMT were modest, and rural patients were less likely to reach at least 50% of target doses for β-blockers and renin-angiotensin system inhibitors.

Rural patients had lower HF readmission (1-year OR, 0.81; 95% CI, 0.79-0.82) but higher mortality at 30 days (OR, 1.10; 95% CI, 1.06-1.14) and 90 days (OR, 1.05; 95% CI, 1.02-1.08), with no significant difference at 1 year (OR, 1.00; 95% CI, 0.98-1.02).

The authors suggested that rural patients may face a pronounced risk of decompensation early after discharge, with delayed follow-up, limited specialty access, and medication affordability as possible contributors. Transitional care, telehealth-based follow-up, outpatient medication optimization, and closer coordination between urban centers and rural clinics may help close that gap, they wrote.

The investigators noted that residual confounding is possible, as rural patients who sought urban care may have had greater resources, and that lower readmission among rural patients may reflect access barriers rather than better clinical stability.

“In this cohort study, among Medicare beneficiaries hospitalized with HFrEF, hospital rurality was associated with differences in process of care, GDMT initiation, and clinical outcomes,” wrote the authors of the study. “Rural patients treated in urban hospitals experienced lower readmission and improved mortality compared with rural patients treated in rural hospitals. However, rural residence remained associated with higher short-term mortality compared with urban patients, even when care was delivered in urban hospitals. These findings highlight the critical role of hospitals and postdischarge transitions of care in shaping the outcomes for rural patients with HFrEF.”


References

  1. Verma A, Fan J, Wei C, et al. Intersection of Patient and Hospital Rurality in Heart Failure Care and Outcomes. JAMA Cardiol. Published online October 30, 2026. doi:10.1001/jamacardio.2026.4827
  2. Pierce JB, Ikeaba U, Peters AE, et al. Quality of care and outcomes among patients hospitalized for heart failure in rural vs urban US hospitals: the Get With The Guidelines-Heart Failure Registry. JAMA Cardiol. 2023;8(4):376-385. doi:10.1001/jamacardio.2023.0241

Related to this article